AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 175.26 |
Market Cap | 310.06B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 2.86 |
PE Ratio (ttm) | 61.35 |
Forward PE | n/a |
Analyst | Buy |
Ask | 176.23 |
Volume | 3,745,559 |
Avg. Volume (20D) | 6,365,329 |
Open | 176.61 |
Previous Close | 176.74 |
Day's Range | 174.14 - 176.78 |
52-Week Range | 153.58 - 207.32 |
Beta | undefined |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...
Analyst Forecast
According to 20 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $205.5, which is an increase of 17.12% from the latest price.
Next Earnings Release
Analysts project revenue of $14.81B, reflecting a 3.56% YoY growth and earnings per share of 2.98, making a 6.81% increase YoY.